Brainsway Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Brainsway Ltd., a foreign private issuer, on June 9, 2026. The filing serves to incorporate by reference a press release regarding clinical data presentation at the Clinical TMS Society Annual Meeting.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on a specific corporate event rather than a financial statement.
Material Changes and Corporate Events
- Clinical Data Presentation: Brainsway presented first 12-month durability data for its SWIFT Accelerated Deep TMS treatment.
- Event: The data was presented at the Clinical TMS Society Annual Meeting.
Guidance, Outlook, and Risks
The filing text does not provide specific financial guidance, management commentary on future outlook, or a detailed discussion of risks and contingencies beyond the context of the clinical data presentation.
Investor Verification Checklist
- Verify the full details and statistical significance of the 12-month durability data for SWIFT Accelerated Deep TMS presented at the Clinical TMS Society Annual Meeting.
- Review the full text of the press release referenced as Exhibit 99.1 for specific clinical outcomes.
- Check subsequent filings for any impact of this data on regulatory approvals or commercial adoption rates.